However, conflicting data have been reported, with a study performed by Maleki et al. [77] reporting results with no statistical significant value of PTX3 in differentiating the degree of fibrosis and with more modest results on the value of PTX3 as a sole biomarker of NAFLD (AUC-0.731); this suggests that it is better used in combination with other biomarkers in order to improve diagnostic accuracy [78]. This evidence concerns the gene PTX3 and metabolic dysfunction-associated steatotic liver disease.